Navigation Links
Possible pharmacological target(s) identified in pediatric OSA
Date:2/4/2010

Children with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring, according to a new study from the University of Chicago, which found that a specific gene product may be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.

"We found that in the tonsil tissues of children with OSA, certain genes and gene networks were over expressed," said David Gozal, M.D., professor and chair of the Department of Pediatrics, who led the study. "We believe that the results of this gene overexpression is increased proliferation of the adenotonsillar tissues, which in turn can cause partial or complete obstruction of the upper airways during sleep."

The findings have been published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In the United States, two to three percent of children have OSA. The current standard of treatment is surgical removal on the tonsils, but surgery is not without risks and potential complications. Currently, about 600,000 tonsillectomies are performed each year in children, primarily to treat OSA.

Dr. Gozal and colleagues have been studying potential non-surgical alternatives to treat OSA in children. To identify potential pharmacological targets, they recruited 18 children with OSA and 18 age-, gender-, and ethnicity-matched children with recurrent tonsillar infections (RI), all of who underwent surgery to have their tonsils removed.

The tonsil tissue from each subject was analyzed for relative expression of the 44,000 known genes in the human genome. The researchers then further analyzed the gene pathways to determine which changes may represent differences with a high likelihood of impact on cellular proliferation.

"We wanted to find the most important and functionally pertinent genes, those with the most connectivity," explained Dr. Gozal. "We identified 47 genes and among those, two specific genes, both phosphatases, which are known to be very important at regulating communication in cells. Then we looked at the expression of the phosphatase protein and found that children with OSA have higher level of phosphatases in the tonsils." In particular, they focused on one protein called phosphoserine phosphatase (PSPH) that was expressed in children with OSA, but almost never expressed in the children with RI.

"We asked, 'What happens if we block this phosphatase?'" said Dr. Gozal. "Is this a potential target for pharmacological therapy?" Indeed, they found that introducing calyculin, a phosphatase inhibitor, reduced the cell proliferation and increased programmed cell death, or apoptosis, a process by which cells self-regulate, in the tonsils of OSA patients. "Together, these observations suggest that PSPH is a logical therapeutic target in reversing adenotonsillar enlargement in pediatric OSA," Dr. Gozal wrote.

"The next direction is to identify if selective clones of proliferating cells that may be affected by PSPH or by another of the discovered target genes with the intent of developing a non-surgical alternative treatment to surgery for OSA in children," said Dr. Gozal. "If there is a subgroup of cells that have specific markers, then we may be able to develop a therapy that could be specifically targeted to these cells."

"Phosphatases such as PSPH are an exciting prospective target for therapy in children with OSA," said Dr. Gozal. "We believe if we had effective non-surgical alternatives to tonsillectomies, it would be of great benefit."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. NIH takes step to assess any possible risk associated with low-dose radiation exposure
2. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
3. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
4. Possible ovarian cancer treatment target identified
5. Urine test for pediatric obstructive sleep apnea possible
6. Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase
7. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
8. Experts Examine Possible Links Between Climate Change and Infectious Disease Transmission
9. Less HRT, Fewer Cases of Possible Breast Cancer Precursor
10. Firm Says Low-Cost Genome Sequencing Is Possible
11. Expert predicts possible shift in senior voting bloc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... ... Goodcents Deli Fresh Subs announced a franchise expansion agreement today including three ... The first new location will open at the corner of 27th and Randolph in ... Drive this fall. And the third location is in the process of being identified. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the ... water-related accidents and drownings during the summer. While most of us assume this type ... occur every day. Very few people are taking the time to learn how to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... management in hospitals, today announced it has completed a round of funding to ... LLC and its partners. Black Granite Capital is a growth equity firm focused ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Journal ... adults. It can have severe consequences to overall dental health, including complications with speech, ... often turn to dental implants to replace lost teeth. As the number of tooth ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the adoption of e-prescribing as measured in Part D Medicare data. The dataset, ... to pharmacies, either using e-prescribing, faxes or paper. The PaPR (pronounced "paper") ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology: